Study of High-dose, Intermittent Sunitinib in Patients With Solid Tumors.

Summary

The primary objective of this study is: * To determine the maximum tolerated dose (MTD) of sunitinib when administered once weekly or once every two weeks. * To assess the safety and tolerability of sunitinib in a once weekly or once every two weeks dose schedule.

Timeline

Start

2013-07

Primary completion

2019-06

Completion

2019-06

Publications

• Rovithi M, Gerritse SL, Honeywell RJ, Ten Tije AJ, Ruijter R, Peters GJ, Voortman J, Labots M, Verheul HMW. Phase I Dose-Escalation Study of Once Weekly or Once Every Two Weeks Administration of High-Dose Sunitinib in Patients With Refractory Solid Tumors. J Clin Oncol. 2019 Feb 10;37(5):411-418. doi: 10.1200/JCO.18.00725. Epub 2018 Dec 26.

Drugs

Indications